Archives

New data suggests high level of disease control possible with combination of dendritic cell therapy and PD-1/PD-L1 checkpoint inhibitors

`s-Hertogenbosch, The Netherlands, 3 April 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, presented data from patients that received a combination of its dendritic cell therapy product MesoPher with marketed checkpoint inhibitors, to treat mesothelioma. The data was presented at the AACR Annual Meeting 2019 in Atlanta, Georgia.

Dendritic Cells (DCs) capture, process, and present antigens to the immune system. However, mesothelioma suppresses the differentiation, maturation and therefore immuno-stimulatory function of